Tekzima is established in 2016 by a group of well experienced scientists. Tekzima thinks to a better service to the community and acts on principles of operational excellence to reach to its goal. By Tekzima’s product, Beraksurf, we change a lethal situation of some newborn infants into a new vital and controlled condition. We serve parents have infant with Respiratory Distress Syndrome (RDS), by presenting an effective treatment by our product, Beraksurf. We have serious commitment to our responsibilities against community, environment and all of our related people including investors and staff. Our values are transparent integrity in all of our responsibilities and achievements. Tekzima is a subsidiary company of Noargen. Tekzima( شرکت تکزیما دارو زیر مجموعه شرکت نوآرژن است.) داروی برکسورف نوع ژنریک داروی براکتانت با نام تجاری سوروانتا است.